1. Health technology

  2. •

    Pharmaceuticals: major
Novartis AG TEMP

Novartis AG TEMP

129.26
CHF
+2.06
(+1.62%)
5.30EPS
23.78P/E
240.62BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
19.31
22.03
21.05
21.21
18.06
19.58
20.6
19.43
17.93
18.46
18.94
23.31
23.22
23.71
Basic EPS, GAAP
3.36
4.19
7.43
2.88
3.2
5.36
4.96
3.14
9.79
2.95
6.03
5.38
5.73
5.34
Free Cash Flow per Basic Share
3.59
4.31
3.51
3.69
4.3
4.94
4.81
4.31
5.1
5.1
4.75
6.22
6.24
6.27
Dividend per Share
2.23
2.8
2.78
2.78
2.7
2.96
2.81
2.72
3
3.19
2.95
3.44
3.2
3.81
Book Value per Share
27.4
29.39
32.59
32.16
31.24
33.5
23.74
22.24
27.68
25.93
19.25
20.28
19.2
17.7
Tangible Book Value per Share
5.7
7.32
4.93
5.38
5.23
1.96
0.07
-4.01
1.59
-0.7
-1.47
-3.51
-3.68
-11.63
Basic Weighted Avg Shares
2,435
2,420
2,397
2,372
2,340
2,313
2,285
2,271
2,238
2,176
2,072
2,013
1,934
1,910
Sales/Revenue/Turnover
47,023
53,304
50,470
50,314
42,264
45,297
47,070
44,144
40,112
40,160
39,245
46,921
44,907
45,278
Operating Margin (%)
20.83
20.68
17.82
16.72
20.05
18.23
18.67
20.35
22.87
18.28
20.94
28.12
31.13
30.18
Depreciation Expense
3,929
4,653
5,480
6,150
4,612
5,120
5,634
5,719
5,105
6,196
6,962
5,506
4,219
4,425
Net Income, GAAP
8,184
10,147
17,812
6,831
7,501
12,392
11,345
7,141
21,911
6,427
12,490
10,833
11,081
10,190
Effective Tax Rate (%)
13.86
12.59
13.6
14.31
17.61
9.19
20.06
18.29
6.62
15.72
6.04
12.47
14.59
17.9
Profit Margin (%)
17.4
19.04
35.29
13.58
17.75
27.36
24.1
16.18
54.63
16
31.83
23.09
24.67
22.5
Working Capital
3,723
10,523
-864
2,770
4,679
5,852
1,199
-2,996
14,148
7,627
3,441
918
2,521
-3,552
LT Debt
10,028
13,714
16,354
18,215
22,614
22,079
21,328
24,752
22,369
20,128
16,850
20,805
23,448
31,628
Total Equity
66,429
70,408
77,249
76,221
72,277
77,323
53,717
50,131
61,865
54,910
39,321
40,030
36,884
33,885
Return on Invested Capital (%)
10.01
10.82
7.99
7.08
6.83
7.03
7.18
8.59
9.56
7.01
10.49
17.26
17.4
16.4
Return on Capital (%)
10.5
12.35
19.37
7.48
8.09
12.66
12.58
9.39
25.99
8.25
18.52
17.92
17.81
16.75
Return on Common Equity (%)
12.63
14.85
24.15
8.91
10.11
16.58
17.33
13.77
39.2
11.03
26.55
27.35
28.97
30.49

Capital Structure

CHF

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,583
6,298
7,967
LT Borrowings
22,135
29,898
30,285
LT Finance Leases
1,313
1,328
1,343
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,904
1,903
1,896
Market Capitalization
208,932
231,920
240,617

Working Capital

CHF

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
24,136
21,244
22,095
Cash, Cash Equivalents & STI
9,139
5,571
6,212
Accounts Receivable, Net
7,082
7,494
7,784
Inventories
4,967
5,019
5,025
Total Current Liabilities
21,615
25,050
25,647
Payables & Accruals
7,541
4,894
5,307
ST Debt
4,583
6,298
7,967
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5.9%
-4.46%
-7.86%
Free Cash Flow
4.41%
5.24%
-3.55%
Net Income, GAAP
18.74%
43.91%
2.29%
Sales/Revenue/Turnover
-0.75%
0.8%
-4.29%
Total Cash Common Dividend
-0.39%
0.56%
-10.43%

Quarterly Revenue

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
10,920
11,563
11,134
12,299
46,921
2025
12,038
11,759
11,420
10,982
44,907
2026
10,798
12,078
- -
- -
- -

Quarterly Earnings Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1.19
1.44
1.34
1.29
5.38
2025
1.62
1.65
1.62
1
5.73
2026
1.32
1.39
- -
- -
- -

Quarterly Dividends Per Share

CHF

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.3
1.07
- -
- -
3.44
2025
2.4
1.01
- -
- -
3.2
2026
2.6
1.22
- -
- -
- -

Company Description

Company Profile APIChatGPT
Address
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business

Company News

Company News APIChatGPT

  • seekingalpha.com

    Novartis: The Sell-Off Creates An Attractive Entry Point

  • reuters.com

    Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • zacks.com

    NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • reuters.com

    US FDA expands use of Novartis drug for chronic skin condition

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • zacks.com

    Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

  • cnbc.com

    Big Pharma turns to China for new drugs as patent cliff drives multibillion-dollar deals

  • wsj.com

    Novartis to License Drug From China's Abogen in Up to $7.8 Billion Deal

  • reuters.com

    Novartis signs mRNA deal for about $7.8 billion with China's Abogen

  • prnewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • gurufocus.com

    Novartis AG (NVS) Shares Fall 0.8% -- What GF Score of 78 Tells Investors

  • globenewswire.com

    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

  • defenseworld.net

    Novartis (NYSE:NVS) Stock Sold by Rep. Kevin Hern

  • zacks.com

    Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs

  • benzinga.com

    Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

  • zacks.com

    NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication

  • defenseworld.net

    Critical Analysis: Redhill Biopharma (NASDAQ:RDHL) versus Novartis (NYSE:NVS)